Published in Cell Signal on January 29, 2016
AR Signaling and the PI3K Pathway in Prostate Cancer. Cancers (Basel) (2017) 0.75
Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer. BMC Cancer (2017) 0.75
The Amino-terminal Domain of the Androgen Receptor Co-opts Extracellular Signal-regulated Kinase (ERK) Docking Sites in ELK1 Protein to Induce Sustained Gene Activation That Supports Prostate Cancer Cell Growth. J Biol Chem (2016) 0.75
Low Dose Dihydrotestosterone Drives Metabolic Dysfunction via Cytosolic and Nuclear Hepatic Androgen Receptor Mechanisms. Endocrinology (2016) 0.75
Cancer statistics, 2015. CA Cancer J Clin (2015) 57.51
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2012) 15.83
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature (1997) 11.15
Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L) Cell (1996) 10.83
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol (2005) 10.48
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature (1991) 9.89
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
The role of general initiation factors in transcription by RNA polymerase II. Trends Biochem Sci (1996) 7.00
The androgen axis in recurrent prostate cancer. Clin Cancer Res (2004) 6.67
In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet (1995) 6.60
A renaissance for SRC. Nat Rev Cancer (2004) 6.27
Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med (1995) 6.26
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res (2009) 6.15
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59
Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res (2012) 5.50
Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell (2009) 5.24
Molecular genetics of prostate cancer. Genes Dev (2000) 5.18
Molecular biology of the androgen receptor. J Clin Oncol (2002) 5.08
Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell (2001) 4.78
Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev (2003) 4.62
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med (1999) 4.20
Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell (2010) 4.16
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest (2008) 4.13
A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun (1990) 3.79
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res (2002) 3.72
Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One (2011) 3.59
Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev (2007) 3.54
Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J (2002) 3.27
Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res (2002) 3.26
Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell (2006) 3.16
Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol (2014) 3.10
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res (2005) 3.08
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int (2005) 3.06
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J (2011) 2.97
Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J (2000) 2.96
Multiple actions of steroid hormones--a focus on rapid, nongenomic effects. Pharmacol Rev (2000) 2.94
A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell (2013) 2.94
Genomic and biochemical insights into the specificity of ETS transcription factors. Annu Rev Biochem (2011) 2.89
Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One (2011) 2.88
The current state of hormonal therapy for prostate cancer. CA Cancer J Clin (2002) 2.74
Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res (2008) 2.59
Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J (1998) 2.58
Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res (2004) 2.55
The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A (1997) 2.54
Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol (2007) 2.53
An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov (2013) 2.52
Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci U S A (2008) 2.47
Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res (2002) 2.46
Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res (2012) 2.45
Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell (2001) 2.44
Src signaling in cancer invasion. J Cell Physiol (2010) 2.44
A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. J Biol Chem (1994) 2.35
Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res (2004) 2.32
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol (2003) 2.32
Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res (2011) 2.25
New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep (2007) 2.17
Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab (2003) 2.16
Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res (2004) 2.15
The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol (2002) 2.12
Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J Biol Chem (2002) 2.08
A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest (1985) 2.04
Retracted Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci U S A (2002) 2.01
AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene (2012) 1.98
Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proc Natl Acad Sci U S A (2007) 1.93
Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem (2006) 1.85
Specific, nongenomic actions of steroid hormones. Annu Rev Physiol (1997) 1.84
Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res (2005) 1.84
Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res (2004) 1.75
Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity. Prostate Cancer Prostatic Dis (1998) 1.73
Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin (2005) 1.70
Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene (2001) 1.67
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci U S A (2013) 1.66
Retracted Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem (2003) 1.63
Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol (1992) 1.60
Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res (2006) 1.60
Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur Urol (2012) 1.60
Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem (2006) 1.59
Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res (1994) 1.59
Nuclear import of the human androgen receptor. Biochem J (1993) 1.58
Nongenomic actions of steroid hormones in reproductive tissues. Endocr Rev (1998) 1.57
Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res (2003) 1.55
Rapid signalling by androgen receptor in prostate cancer cells. Oncogene (1999) 1.54
Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res (2009) 1.54
Selective DNA binding by the androgen receptor as a mechanism for hormone-specific gene regulation. J Steroid Biochem Mol Biol (2001) 1.53
Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther (2005) 1.53
Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer (2002) 1.53
C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res (2003) 1.52
Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene (2004) 1.48
Non-genomic actions of androgens. Front Neuroendocrinol (2007) 1.48
Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science (2014) 1.45
Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry (1992) 1.44
Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc. Mol Endocrinol (2004) 1.44